Neuroprotective effects of sinapic acid involve the iron regulatory role on the rotenone-induced Parkinson’s disease model

Bahattin Avcı; Caner Günaydın; Mustafa Kulbay; Nilüfer Kuruca; Tolga Güvenç; Süleyman Sırrı Bilge

doi:10.1590/s2175-97902022e20942

Autores

Bahattin Avcı Ondokuz Mayıs University, School of Medicine, Department of Biochemistry, Samsun, Turkey
Caner Günaydın Ondokuz Mayıs University, School of Medicine, Department of Pharmacology, Samsun, Turkey
Mustafa Kulbay Ondokuz Mayıs University, School of Medicine, Department of Biochemistry, Samsun, Turkey
Nilüfer Kuruca Ondokuz Mayıs University, Faculty of Veterinary, Department of Pathology, Samsun, Turkey
Tolga Güvenç Ondokuz Mayıs University, Faculty of Veterinary, Department of Pathology, Samsun, Turkey https://orcid.org/0000-0003-1468-3415
Süleyman Sırrı Bilge https://orcid.org/0000-0003-2878-6968

DOI:

https://doi.org/10.1590/s2175-97902022e20942

Palavras-chave:

Sinapic acid, Parkinson’s disease, Rotenone, Iron

Resumo

In the last decades, ferroptosis and its relationship with Parkinson’s disease have gained significant attention. Compounds that affect ferroptosis and iron-dependent pathways in particular, have possible candidates for study in this context.Sinapic acid is an iron-chelator and high antioxidant bioactive phenolic acid. Its neuroprotective action, due to the antioxidant capacity, has been shown in several experimental models.However, the relationship between iron and antioxidant actions is still misunderstood and therefore, in the current study, we tried to investigate the effects of sinapic acid in rotenone-induced Parkinson’s disease with the aspect of ferroptosis and iron-dependent alterations.The Parkinson’s disease model was induced by a single dose intrastriatal and intrategmental rotenone (5µg/µl) injection.Sinapic acid (30mg/ kg) was orally administered during a 28-day period after the Parkinson’s disease model was validated.Our results demonstrated that sinapic acid treatment attenuated rotenone-induced increase of serum transferrin and iron levels.Furthermore, sinapic acid inhibited rotenone-induced heme oxygenase-1(HO-1) increase and decrease of glutathione peroxidase-4 (GPx-4) levels in brain tissue. Also, sinapic acid treatment decreased motor impairment, likely as a result of the ameliorative effects on the tyrosine hydroxylase immunoreactivity loss after the rotenone insult.Our study suggests that the iron regulatory role of sinapic acid possibly plays a role in the protective effect on rotenone-induced neuronal damage.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

Amsen D, de Visser KE, Town T. Approaches to determine expression of inflammatory cytokines. Methods Mol Biol. 2009;511:107-142.

Ayaydin H, Akaltun I, Koyuncu I, Celik H, Kirmit A, Takatak H. High KEAP1, NRF2 and low HO-1 serum levels in children with autism. Noro Psikiyatr Ars. 2020;57(4):274-279.

Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson’s diseases and Is a sufficient cause of neurodegeneration. Biomed Res Int. 2014;2014:581256.

Baker HM, Anderson BF, Baker EN. Dealing with iron: common structural principles in proteins that transport iron and heme. Proc Natl Acad Sci U S A. 2003;100(7):3579-83.

Blevins JE, Stanley BG, Reidelberger RD. DMSO as a vehicle for central injections: tests with feeding elicited by norepinephrine injected into the paraventricular nucleus. Pharmacol Biochem Behav. 2002;71(1-2):277-82.

Cardoso BR, Hare DJ, Bush AI, Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration? Mol Psychiatry. 2017;22(3):328-335.

Chen C. Sinapic Acid and Its Derivatives as Medicine in Oxidative Stress-Induced Diseases and Aging. Oxid Med Cell Longev. 2016;2016:3571614.

Filograna R, Beltramini M, Bubacco L, Bisaglia M. Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View. Curr Neuropharmacol. 2016;14(3):260-71.

Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180-91.

Greenamyre JT, Hastings TG. Parkinson’s--divergent causes, convergent mechanisms. Science. 2004;304(5674):1120-2.

Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, Morgadinho AS, et al. Association of HFE common mutations with Parkinson’s disease, Alzheimer’s disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 2006;6:24.

Hynes MJ, O’Coinceanainn M. The kinetics and mechanisms of reactions of iron(III) with caffeic acid, chlorogenic acid, sinapic acid, ferulic acid and naringin. J Inorg Biochem. 2004;98(8):1457-64.

Janda E, Isidoro C, Carresi C, Mollace V. Defective autophagy in Parkinson’s disease: role of oxidative stress. Mol Neurobiol. 2012;46(3):639-61.

Jerussi TP, Glick SD. Apomorphine-induced rotation in normal rats and interaction with unilateral caudate lesions. Psychopharmacologia. 1975;40(4):329-34.

Kabiraj P, Valenzuela AC, Marin JE, Ramirez DA, Mendez L, Hwang MS, et al. The neuroprotective role of ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells. Protein. 2015;34(5):349-58.

Kanchana G, Shyni WJ, Malini P, Rajadurai M. Effect of sinapic acid on antiperoxidative and antioxidant potential in normal and streptozotocin-induced diabetes in wistar rats. Int J Pharm Clin Res. 2011;3(1):05-09.

Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron. 2003;37(6):899-909.

Kose T, Vera-Aviles M, Sharp PA, Latunde-Dada GO. Curcumin and (-)-epigallocatechin-3-gallate protect murine min6 pancreatic beta-cells against iron toxicity and erastin-induced ferroptosis. Pharmaceuticals (Basel). 2019;12(1):26.

LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet. 2001;27(2):209-14.

Lee HE, Kim DH, Park SJ, Kim JM, Lee YW, Jung JM, et al. Neuroprotective effect of sinapic acid in a mouse model of amyloid beta(1-42) protein-induced Alzheimer’s disease. Pharmacol Biochem Behav . 2012;103(2):260-6.

Lee JY. Anti-inflammatory effects of sinapic acid on 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. Arch Pharm Res. 2018;41(2):243-250.

Lesjak M, Srai SKS. Role of Dietary Flavonoids in Iron Homeostasis. Pharmaceuticals (Basel). 2019;12(3):119.

Li X, Duan L, Yuan S, Zhuang X, Qiao T, He J. Ferroptosis inhibitor alleviates radiation-induced lung fibrosis (RILF) via down-regulation of TGF-β. J Inflamm (Lond). 2019;16:11.

Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016;73(17):3221-47.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75.

Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci. 2002;15(1):120-32.

Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017;7(1):1398.

Mastroberardino PG, Hoffman EK, Horowitz MP, Betarbet R, Taylor G, Cheng D, et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson’s disease. Neurobiol Dis. 2009;34(3):417-31.

Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34. DOI: 10.1186/s13045-019-0720-y

» https://doi.org/10.1186/s13045-019-0720-y

Murphy MP. Antioxidants as therapies: can we improve on nature? Free Radic Biol Med. 2014;66:20-3.

Nomura K, Imai H, Koumura T, Kobayashi T, Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. Biochem J. 2000;351(Pt 1):183-93.

Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 4th edition, Elsevier/Academic, 2009.

Percario S, Barbosa AS, Varela ELP, Gomes ARQ, Ferreira MES, Nazaré T, et al. Oxidative stress in Parkinson’s disease: Potential benefits of antioxidant supplementation. Oxid Med Cell Longevity. 2020;2360872:23.

Rao SR, Olechnowicz SWZ, Kratschmer P, Jepson JEC, Edwards CM, Edwards JR. Small Animal Video Tracking for Activity and Path Analysis Using a Novel Open-Source Multi-Platform Application (AnimApp). Sci Rep . 2019;9(1):12343.

Schipper HM, Liberman A, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson’s disease. Exp Neurol. 1998;150(1):60-8.

Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci. 2003;23(34):10756-64.

Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem. 2011;118(6):939-57.

Song W, Cressatti M, Zukor H, Liberman A, Galindez C, Schipper HM. Parkinsonian features in aging GFAP. HMOX1 transgenic mice overexpressing human HO-1 in the astroglial compartment. Neurobiol Aging. 2017;58:163-179.

Song W, Zukor H, Liberman A, Kaduri S, Arvanitakis Z, Bennett DA, et al. Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. Exp Neurol . 2014;254:78-89.

Sutachan JJ, Casas Z, Albarracin SL, Stab 2nd BR, Samudio I, Gonzalez J, et al. Cellular and molecular mechanisms of antioxidants in Parkinson’s disease. Nutr Neurosci. 2012;15(3):120-6.

Tamilselvam K, Braidy N, Manivasagam T, Essa MM, Prasad NR, Karthikeyan S, et al. Neuroprotective effects of hesperidin, a plant flavanone, on rotenone-induced oxidative stress and apoptosis in a cellular model for Parkinson’s disease. Oxid Med Cell Longev . 2013;2013:102741.

Verma R, Nehru B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson’s disease. Neurochem Int. 2009;55(6);369-375.

Wang G, Wu Y, Zhou T, Guo Y, Zheng B, Wang J, et al. Mapping of the N-linked glycoproteome of human spermatozoa. J Proteome Res. 2013;12(12):5750-9.

Zare K, Eidi A, Roghani M, Rohani AH. The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat. Metab Brain Dis. 2015;30(1):205-13.

Zych M, Kaczmarczyk-Sedlak I, Wojnar W, Folwarczna J. The effects of sinapic acid on the development of metabolic disorders induced by estrogen deficiency in rats. Oxid Med Cell Longev . 2018;2018:9274246.

Neuroprotective effects of sinapic acid involve the iron regulatory role on the rotenone-induced Parkinson’s disease model

Autores

DOI:

Palavras-chave:

Resumo

Downloads

Referências

Downloads

Publicado

Edição

Seção

Licença

Como Citar

Dados de financiamento